Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:06:49 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:VRDN - VIRIDIAN THERAPEUTICS INC - https://www.viridiantherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRDN - Q0.115.38·17.500.516.82-0.61-3.51,614.326,14015,75817.26  17.38  16.7134.29  12.4819:58:31May 0615 min RT 2¢

Recent Trades - Last 10 of 15758
Time ETExPriceChangeVolume
19:58:31Q16.80-0.63290
19:16:27Q16.72-0.7110
19:15:27Q16.85-0.58100
18:45:47Q16.85-0.5857
17:30:44Q16.9989-0.431142
16:24:13Q16.95-0.4850
16:13:35Q16.82-0.611,170
16:10:05Q16.82-0.611
16:10:05Q16.82-0.611
16:10:04Q16.82-0.611

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-06 23:13U:VRDNNews ReleaseViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
2026-05-05 16:05U:VRDNNews ReleaseViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
2026-05-05 07:01U:VRDNNews ReleaseViridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2026-03-30 07:01U:VRDNNews ReleaseViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease
2026-02-26 07:01U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-08 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 07:01U:VRDNNews ReleaseViridian Therapeutics Prepares for Transformational 2026
2025-12-22 07:00U:VRDNNews ReleaseViridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
2025-12-05 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-05 07:01U:VRDNNews ReleaseViridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
2025-11-03 07:01U:VRDNNews ReleaseViridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
2025-10-21 23:24U:VRDNNews ReleaseViridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
2025-10-21 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Proposed Underwritten Public Offering
2025-10-20 07:30U:VRDNNews ReleaseViridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
2025-10-02 16:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-15 07:01U:VRDNNews ReleaseViridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
2025-09-03 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-06 06:30U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
2025-08-04 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)